Skip to main content
. Author manuscript; available in PMC: 2014 May 15.
Published in final edited form as: Science. 2013 Oct 17;342(6160):866–871. doi: 10.1126/science.1243292

Table 1. Summary of clinical and immunological features of patients with the E1021K p110δ mutation.

Clinical / Immunological manifestation Patients Frequency,
n / total studied (%)
Recurrent respiratory and ear infections (H. influenzae, S. pneumoniae) P1-17 17/17 (100)
CT evidence of large (bronchiectasis) or small (mosaic attenuation) airway disease P1-7,9,11-13,17 12/16 (75)
Splenomegaly (prior to the onset of recurrent infections) P2,3,5,6,8,9,13-16 10/17 (59)
Skin, salivary gland, lacrimal gland or dental abscess formation, orbital cellulitis P1,3,5-8,10 7/17 (41)
Infection caused by herpes group viruses (HSV, CMV, VZV, EBV) P3,8,12,13 (and the deceased
sister of P5/P6)
4/17 (24)
Marginal zone lymphoma P13 1/17 (6)

Low/intermittent low serum IgG2 levels P2-7,10-13 10/11 (91)
High/intermittent high serum IgM levels P1-6,8-11,13-16 14/17 (82)
Low levels of anti-pneumococcal antibodies P1-4,7,9,11-13,17 10/10 (100)
Low levels of anti-Haemophilus Influenzae type B antibodies P1-4,8,9,12,13 8/10 (80)
Decreased circulating T cells (total CD3+) and/or CD4+ and/or CD8+ T cells P1-9,13,14,17 12/17 (71)
Decreased circulating B cells (total CD19+) P2-9,13,14-16 12/17 (71)
Increased circulating transitional B cells (CD19+CD38+IgM+) P1-4,7-14,16,17 14/16 (88)
Decreased circulating class switched memory B cells (CD19+CD27+IgD−) P1-3,8,9,12,13,16 8/16 (50)